Healthcare
Live Price
Offline$17.34
+0.00% today
Window Change
-6.96%
Window
May 26, 2026 → Jun 12, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 14 bars · May 26, 2026 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PureTech Health plc (PRTC) is a Healthcare stock with a market cap of $440.00M and listed on NASDAQ. The stock last traded around $17.34 and down 7.0% across the available one-year price window (May 26, 2026 → Jun 12, 2026). Baseline metrics include revenue growth of -3.5%, EPS growth of -2400.0%, a dividend yield of 0.0%. What stands out right now is revenue -3.5%, EPS -2400.0%, free cash flow +36.5% with operating margin -2115.4% and ROIC -19.6%. Valuation already assumes a fairly strong business story at price/sales 95.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRTC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRTC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRTC Max Drawdown
-10.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRTC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.3M
-16.4% YoY
FY Net Income
$6.0M
+109.9% YoY
Free Cash Flow
-$137.3M
+16.3% YoY
Revenue Growth
-3.5%
EPS Growth
-2400.0%
Gross Margin
-471.2%
Net Margin
-2355.5%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 5M | 3M | 2M | 10M | 8M |
| Gross Profit | 1M | -2M | -137M | -100M | 8M |
| Operating Income | -136M | -146M | -198M | -150M | -120M |
| EBITDA | 37M | -12M | -189M | 27M | 63M |
| Net Income | 54M | -66M | -50M | -61M | 6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 281M | 191M | 150M | 466M | 404M |
| Total Assets | 603M | 694M | 703M | 946M | 990M |
| Total Liabilities | 195M | 236M | 155M | 362M | 336M |
| Shareholder Equity | 415M | 464M | 542M | 594M | 670M |
| Total Debt | 22M | 25M | 47M | 53M | 77M |
| Net Debt | -258M | -166M | -103M | -414M | -327M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
132M
+16.7% YoY
Capital Expenditures
5M
+4.2% YoY
Free Cash Flow
137M
+16.3% YoY
Key ratios
Gross Margin
-471.2%
Operating Margin
-2115.4%
Net Margin
-2355.5%
ROE
-31.8%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.